Literature DB >> 17158642

Expression of EphA2 and EphrinA-1 in vulvar carcinomas and its relation to prognosis.

R Holm1, S Knopp, Z Suo, C Tropè, J M Nesland.   

Abstract

AIMS: To examine the expression of EphA2 and EphrinA-1 in vulvar squamous cell carcinomas and investigate their prognostic relevance.
METHODS: Tumours from 224 patients with vulvar squamous cell carcinomas were investigated for expression of EphA2 and EphrinA-1 using single and double immunostaining methods.
RESULTS: High expression (strong/moderate staining intensity) of EphA2 and EphrinA-1 was observed in 114 (51%) and 126 (56%) vulvar carcinomas, respectively. In the three cases tested using the double immunostaining method, colocalisation of EphA2 and EphrinA-1 proteins was identified in the same neoplastic cells. High EphA2 expression was significantly correlated to high expression of EphrinA-1 (p<0.01) and cyclin A (p<0.01), large tumour size (p = 0.03), deep invasion (p<0.01) and higher FIGO stage (p = 0.05). A correlation between high EphrinA-1 expression and high levels of cyclin A (p<0.01) and p21 (p<0.01), deep invasion (p<0.01) and higher FIGO stage (p = 0.01) was also seen. In univariate analysis, high expression of EphrinA-1 was associated with poor survival (p = 0.03). However, in the multivariate analysis neither EphrinA-1 nor EphA2 were significantly correlated to survival.
CONCLUSIONS: EphA2 and EphrinA-1 were overexpressed in 51% and 56% of the vulvar squamous cell carcinomas, respectively, and high levels of EphA2 and EphrinA-1 proteins were associated with deep tumour invasion and high FIGO stage. However, EphA2 and EphrinA-1 were not independently associated with clinical outcome in vulvar carcinomas.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17158642      PMCID: PMC2014830          DOI: 10.1136/jcp.2006.041194

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  36 in total

1.  A novel immediate-early response gene of endothelium is induced by cytokines and encodes a secreted protein.

Authors:  L B Holzman; R M Marks; V M Dixit
Journal:  Mol Cell Biol       Date:  1990-11       Impact factor: 4.272

2.  Prognostic indicators for invasive carcinoma of the vulva.

Authors:  F N Rutledge; M F Mitchell; M F Munsell; E N Atkinson; S Bass; V McGuffee; E Silva
Journal:  Gynecol Oncol       Date:  1991-09       Impact factor: 5.482

3.  cDNA cloning and characterization of eck, an epithelial cell receptor protein-tyrosine kinase in the eph/elk family of protein kinases.

Authors:  R A Lindberg; T Hunter
Journal:  Mol Cell Biol       Date:  1990-12       Impact factor: 4.272

4.  B61 is a ligand for the ECK receptor protein-tyrosine kinase.

Authors:  T D Bartley; R W Hunt; A A Welcher; W J Boyle; V P Parker; R A Lindberg; H S Lu; A M Colombero; R L Elliott; B A Guthrie
Journal:  Nature       Date:  1994-04-07       Impact factor: 49.962

5.  Carcinoma of the vulva: analysis of treatment failures.

Authors:  K C Podratz; R E Symmonds; W F Taylor
Journal:  Am J Obstet Gynecol       Date:  1982-06-01       Impact factor: 8.661

6.  p16INK4a and p21Waf1/Cip1 expression correlates with clinical outcome in vulvar carcinomas.

Authors:  Synne Knopp; Tone Bjørge; Jahn M Nesland; Claes Tropé; Marit Scheistrøen; Ruth Holm
Journal:  Gynecol Oncol       Date:  2004-10       Impact factor: 5.482

7.  Expression of two novel eph-related receptor protein tyrosine kinases in mammary gland development and carcinogenesis.

Authors:  A C Andres; H H Reid; G Zürcher; R J Blaschke; D Albrecht; A Ziemiecki
Journal:  Oncogene       Date:  1994-05       Impact factor: 9.867

8.  Antiangiogenic and antitumor efficacy of EphA2 receptor antagonist.

Authors:  Pawel Dobrzanski; Kathryn Hunter; Susan Jones-Bolin; Hong Chang; Candy Robinson; Sonya Pritchard; Hugh Zhao; Bruce Ruggeri
Journal:  Cancer Res       Date:  2004-02-01       Impact factor: 12.701

9.  Protein B61 as a new growth factor: expression of B61 and up-regulation of its receptor epithelial cell kinase during melanoma progression.

Authors:  D J Easty; B A Guthrie; K Maung; C J Farr; R A Lindberg; R J Toso; M Herlyn; D C Bennett
Journal:  Cancer Res       Date:  1995-06-15       Impact factor: 12.701

10.  EphA2 expression is associated with aggressive features in ovarian carcinoma.

Authors:  Premal H Thaker; Michael Deavers; Joseph Celestino; Angela Thornton; Mavis S Fletcher; Charles N Landen; Michael S Kinch; Peter A Kiener; Anil K Sood
Journal:  Clin Cancer Res       Date:  2004-08-01       Impact factor: 12.531

View more
  9 in total

1.  Ephrin receptor (Eph) -A1, -A2, -A4 and -A7 expression in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival.

Authors:  Stamatios Theocharis; Jerzy Klijanienko; Constantinos Giaginis; Paraskevi Alexandrou; Efstratios Patsouris; Xavier Sastre-Garau
Journal:  Pathol Oncol Res       Date:  2013-09-11       Impact factor: 3.201

2.  Immunohistochemical demonstration of EphA2 processing by MT1-MMP in invasive cutaneous squamous cell carcinoma.

Authors:  Ryoko Tatsukawa; Kaori Koga; Mikiko Aoki; Naohiko Koshikawa; Shinichi Imafuku; Juichiro Nakayama; Kazuki Nabeshima
Journal:  Virchows Arch       Date:  2016-04-07       Impact factor: 4.064

Review 3.  Emerging strategies for EphA2 receptor targeting for cancer therapeutics.

Authors:  Manish Tandon; Sai Vikram Vemula; Suresh K Mittal
Journal:  Expert Opin Ther Targets       Date:  2011-01       Impact factor: 6.902

4.  Clinical significance of ephrin (eph)-A1, -A2, -a4, -a5 and -a7 receptors in pancreatic ductal adenocarcinoma.

Authors:  Constantinos Giaginis; Gerasimos Tsourouflis; Adamantia Zizi-Serbetzoglou; Gregorios Kouraklis; Elli Chatzopoulou; Konstantina Dimakopoulou; Stamatios E Theocharis
Journal:  Pathol Oncol Res       Date:  2009-12-01       Impact factor: 3.201

5.  Expressions of EphA2 and EphrinA-1 in early squamous cell cervical carcinomas and their relation to prognosis.

Authors:  Ruth Holm; Gregg Van de Putte; Zhenhe Suo; A Kathrine Lie; Gunnar B Kristensen
Journal:  Int J Med Sci       Date:  2008-06-05       Impact factor: 3.738

6.  Lack of ephrin receptor A1 is a favorable independent prognostic factor in clear cell renal cell carcinoma.

Authors:  Marieta I Toma; Kati Erdmann; Michael Diezel; Matthias Meinhardt; Stefan Zastrow; Susanne Fuessel; Manfred P Wirth; Gustavo B Baretton
Journal:  PLoS One       Date:  2014-07-15       Impact factor: 3.240

7.  EPHA2, EPHA4, and EPHA7 Expression in Triple-Negative Breast Cancer.

Authors:  Ilias Nikas; Constantinos Giaginis; Kalliopi Petrouska; Paraskevi Alexandrou; Artemis Michail; Panagiotis Sarantis; Gerasimos Tsourouflis; Eugene Danas; Alexandros Pergaris; Panagiotis K Politis; Lydia Nakopoulou; Stamatios Theocharis
Journal:  Diagnostics (Basel)       Date:  2022-02-01

8.  High EphA2 protein expression in renal cell carcinoma is associated with a poor disease outcome.

Authors:  Jinsheng Xu; Junxia Zhang; Liwen Cui; Huiran Zhang; Shenglei Zhang; Yaling Bai
Journal:  Oncol Lett       Date:  2014-05-28       Impact factor: 2.967

9.  Ephrin (Eph) receptor A1, A4, A5 and A7 expression in human non-small cell lung carcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients' survival.

Authors:  Constantinos Giaginis; Nikolaos Tsoukalas; Evangelos Bournakis; Paraskevi Alexandrou; Nikolaos Kavantzas; Efstratios Patsouris; Stamatios Theocharis
Journal:  BMC Clin Pathol       Date:  2014-02-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.